These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16470950)

  • 21. [Medical, non-endocrine treatment of metastatic breast cancer--a status].
    Lindberg H; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Apr; 169(17):1556-60. PubMed ID: 17484824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 23. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 24. Adjuvant trastuzumab for breast cancer.
    Dent R; Clemons M
    BMJ; 2005 Nov; 331(7524):1035-6. PubMed ID: 16269471
    [No Abstract]   [Full Text] [Related]  

  • 25. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 26. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 28. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 29. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.
    Rodrigues MJ; Wassermann J; Albiges L; Brain E; Delaloge S; Stevens D; Guinebretière JM; Mathieu MC; Kirova Y; Guillot E; Vincent-Salomon A; Cottu PH
    J Clin Oncol; 2010 Oct; 28(28):e541-2. PubMed ID: 20660834
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neo(adjuvant) trastuzumab treatment: current perspectives.
    Iwata H
    Breast Cancer; 2009; 16(4):288-94. PubMed ID: 19609648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular targeting therapy for breast neoplasms].
    Horiguchi J
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():415-21. PubMed ID: 17682186
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic adjuvant therapies and radiotherapy to the conserved breast: strategies revisited.
    Bartelink H
    Breast; 2007 Dec; 16 Suppl 2():S84-8. PubMed ID: 17719782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current perspective - trastuzumab.
    Hall PS; Cameron DA
    Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.
    Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17582927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
    Coulson SG; Kumar VS; Manifold IM; Hatton MQ; Ramakrishnan S; Dunn KS; Purohit OP; Bridgewater C; Coleman RE
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):289-93. PubMed ID: 20347281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.